type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Department of Endocrinology and Metabolism, Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A. diabetes group: 1) hospitalized patients with type 2 diabetes 2) HbA1c>8.5% 3) fasting plasma glucose >160 mg/dL or postprandial plasma glucose >250 mg/dL B. non-diabetic group: 1) HbA1c<6.0% and fasting plasma glocose <110 mg/dL 2) no past history of diabetes mellitus
Exclusion criteria
Exclusion criteria: 1) patients with active chronic infectious diseases such as tuberculosis 2) patients with acute infectious diseases such as pneumonia 3) patients with history of chronic inflammatorys diseases such as rheumatoid arthritis 4) patients with history of cancer 5) immunodeficient patients such as those with AIDS 6) patients taking immunosuppressant, steroids, and anti-cancer drugs 7) pregnant, potentially pregnant or lactating women 8) patients with moderate renal dysfunction (male serum creatinin 1.3 mg/dL or higher, female 1.2 mg/dL or higher)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the expression levels of co-inhibitors on peripheral blood T lymphocytes between type 2 diabetes and non-diabetic patients | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the expression levels of co-inhibitors on peripheral blood T lymphocytes before and after the improvement of blood glucose level in type 2 diabetes patients | — |
Countries
Japan
Contacts
Public ContactIsao Usui
Dokkyo Medical University Department of Endocrinology and Metabolism
Outcome results
None listed